These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 30711629)

  • 1. MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1.
    Li H; Li CW; Li X; Ding Q; Guo L; Liu S; Liu C; Lai CC; Hsu JM; Dong Q; Xia W; Hsu JL; Yamaguchi H; Du Y; Lai YJ; Sun X; Koller PB; Ye Q; Hung MC
    Gastroenterology; 2019 May; 156(6):1849-1861.e13. PubMed ID: 30711629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
    Zhao S; Wu W; Jiang H; Ma L; Pan C; Jin C; Mo J; Wang L; Wang K
    Front Immunol; 2021; 12():731527. PubMed ID: 34804015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.
    Torrens L; Montironi C; Puigvehí M; Mesropian A; Leslie J; Haber PK; Maeda M; Balaseviciute U; Willoughby CE; Abril-Fornaguera J; Piqué-Gili M; Torres-Martín M; Peix J; Geh D; Ramon-Gil E; Saberi B; Friedman SL; Mann DA; Sia D; Llovet JM
    Hepatology; 2021 Nov; 74(5):2652-2669. PubMed ID: 34157147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.
    Xiang Q; Zhen Z; Deng DY; Wang J; Chen Y; Li J; Zhang Y; Wang F; Chen N; Chen H; Chen Y
    J Exp Clin Cancer Res; 2015 Oct; 34():118. PubMed ID: 26458953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tivantinib: critical review with a focus on hepatocellular carcinoma.
    Rota Caremoli E; Labianca R
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1563-74. PubMed ID: 25307444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer.
    Ma YF; Chen C; Li D; Liu M; Lv ZW; Ji Y; Xu J
    Oncotarget; 2017 Jan; 8(5):7614-7624. PubMed ID: 27935862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
    Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
    Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
    Zhou SL; Zhou ZJ; Hu ZQ; Huang XW; Wang Z; Chen EB; Fan J; Cao Y; Dai Z; Zhou J
    Gastroenterology; 2016 Jun; 150(7):1646-1658.e17. PubMed ID: 26924089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors.
    Bagai R; Fan W; Ma PC
    IDrugs; 2010 Jun; 13(6):404-14. PubMed ID: 20506063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-PD-L1 antibodies promote cellular proliferation by activating the PD-L1-AXL signal relay in liver cancer cells.
    Tanaka T; Koga H; Suzuki H; Iwamoto H; Sakaue T; Masuda A; Nakamura T; Akiba J; Yano H; Torimura T; Kawaguchi T
    Hepatol Int; 2024 Jun; 18(3):984-997. PubMed ID: 37553470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tivantinib in hepatocellular carcinoma.
    Trojan J; Zeuzem S
    Expert Opin Investig Drugs; 2013 Jan; 22(1):141-7. PubMed ID: 23167786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma.
    Wei K; Li M; Zöller M; Wang M; Mehrabi A; Hoffmann K
    Cell Death Dis; 2019 Mar; 10(3):231. PubMed ID: 30850583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABL1, Overexpressed in Hepatocellular Carcinomas, Regulates Expression of NOTCH1 and Promotes Development of Liver Tumors in Mice.
    Wang F; Hou W; Chitsike L; Xu Y; Bettler C; Perera A; Bank T; Cotler SJ; Dhanarajan A; Denning MF; Ding X; Breslin P; Qiang W; Li J; Koleske AJ; Qiu W
    Gastroenterology; 2020 Jul; 159(1):289-305.e16. PubMed ID: 32171747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.
    Buurman R; Gürlevik E; Schäffer V; Eilers M; Sandbothe M; Kreipe H; Wilkens L; Schlegelberger B; Kühnel F; Skawran B
    Gastroenterology; 2012 Sep; 143(3):811-820.e15. PubMed ID: 22641068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice.
    Li G; Liu D; Kimchi ET; Kaifi JT; Qi X; Manjunath Y; Liu X; Deering T; Avella DM; Fox T; Rockey DC; Schell TD; Kester M; Staveley-O'Carroll KF
    Gastroenterology; 2018 Mar; 154(4):1024-1036.e9. PubMed ID: 29408569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.